Solid Tumor Clinical Trials

 

St. Jude Clinical Trials

FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors

Diseases Treated:

Neuroblastoma, pheochromocytoma

Eligibility:

This study is open to St. Jude patients only.

  • Known or suspected neuroblastoma or pheochromocytoma
  • At least 1 year old

 

View Trial

iRET: Intravitreal Chemotherapy for Children with Retinoblastoma

Diseases Treated:

Retinoblastoma

Eligibility:

  • Age 17 or younger
  • Diagnosis of retinoblastoma that did not go away with treatment or came back after treatment
View Trial

RBAPP: Smartphone App for Retinoblastoma

Diseases Treated:

Retinoblastoma

Eligibility:

This study is currently open only to patients at St. Jude Children's Research Hospital.

  • 7 years old or younger
  • Part I
    • Diagnosed with retinoblastoma and has not received any treatment OR
    • Diagnosed with cataracts and has not received any treatment OR
    • Diagnosed with glaucoma and has not received any treatment
  • Part II
    • Referred to an eye doctor to check for leukocoria or other eye conditions
  • Part III
    • Diagnosed with retinoblastoma and is receiving treatment
View Trial

RMS13: Chemotherapy, Surgery and Proton Beam Radiation Therapy in Treating Patients with Newly Diagnosed Rhabdomyosarcoma

Diseases Treated:

Rhabdomyosarcoma (low-risk, intermediate-risk and high-risk)

Eligibility:

  • Newly diagnosed rhabdomyosarcoma
  • Younger than 22 years (eligible until 22nd birthday)
  • No previous treatment with chemotherapy or radiation therapy
View Trial

SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors

Diseases Treated:

Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

Eligibility:

  • Has one of these types of tumors:
    • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
    • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
    • ATRTs or MRTs that are growing after previous treatment (progressive disease)
  • 21 years of age or younger
View Trial

SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma

Diseases Treated:

Retinoblastoma

Eligibility:

  • Newly diagnosed retinoblastoma that has not spread beyond the eye
  • Has not received previous treatment with chemotherapy or radiation therapy
  • Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
View Trial

Collaborative Clinical Trials

A031102: Standard-Dose Combination Chemotherapy Compared to High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Diseases Treated:

Germ cell tumors

Eligibility:

  • 14 years old or older
  • Diagnosis of germ cell tumor (GCT)
  • Previously received 3 to 6 cycles of cisplatin-based chemotherapy
  • No more than one prior line of chemotherapy
  • No prior treatment with high-dose chemotherapy
View Trial

ACNS1721: A Study of the Drug Veliparib with Radiation Therapy in Patients with Newly Diagnosed High-Grade Glioma

Diseases Treated:

High-grade glioma

Eligibility:

  • 3 to 25 years old
  • Newly diagnosed high-grade-glioma[SJ1] , such as anaplastic astrocytoma or glioblastoma
  • Negative test for H3 K27M mutation
  • Negative test for BRAFV600 mutation
View Trial

ADV1312: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Diseases Treated:

Relapsed or refractory solid tumors

Eligibility:

  • Participant is >12 months and < 21 years of age at the time of study entry.
  • Participant has had histologic verification of malignancy at original diagnosis or relapse.
  • Participant has serum tumor markers including alpha-fetoprotein or beta-HCG.
  • Participant has a relapsed or refractory solid tumor.
View Trial

ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors

Diseases Treated:

Solid Tumors

Eligibility:

  • Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
  • Fully recovered from the acute toxic effects of all prior anticancer therapy
  • At least 1 but not more than 21 years of age
  • Able to swallow tablets whole
View Trial

LOXO-TRK: Testing Larotrectinib (LOXO-101) in Children with Advanced Solid Tumors or Brain Tumors

Diseases Treated:

Solid Tumors, Central Nervous System Tumors

Eligibility:

Phase 1

  • Birth through 21 years of age with locally advanced or metastatic solid tumor or primary CNS tumor that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
  • Infants from birth and older with diagnosis of malignancy and with documented NTRK fusion that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
  • Patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery or limb amputation to achieve complete surgical resection

Phase 2

  • Infants from birth and older at C1D1 with locally advanced or metastatic infantile fibrosarcoma OR
  • Birth through 21 years old at C1D1 with locally advanced or metastatic solid tumor or primary CNS tumor that has relapsed, progressed or was not responsive to therapy and for which no standard or available curative therapy with a NTRK gene funsion OR
  • More than 21 years old with tumor diagnosis typical of a pediatric patient and an NTRK fusion
View Trial

LOXORET: Phase I/II Study of LOXO-292 in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors

Diseases Treated:

Solid tumors, Brain tumors

Eligibility:

  • 6 months to 21 years old
  • Solid tumor or brain tumor that has progressed or spread
  • Failed standard treatment
  • RET gene alteration
View Trial

MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

Diseases Treated:

Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

Eligibility:

  • Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
  • Between 12 years and 18 years old with diagnosis of melanoma OR
  • Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma
  • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
  • Appropriate liver and kidney functions
View Trial

NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma

Diseases Treated:

Neuroblastoma, ganglioneuroblastoma

Eligibility:

  • Participant has been enrolled on ANBLB1 (ANBL00B1).
  • Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
  • Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.

 

View Trial

OSTPDL1: A Phase II Trial of Avelumab for Patients with Recurrent or Progressive Osteosarcoma

Diseases Treated:

Osteosarcoma

Eligibility:

  • At least 12 years old and younger than 25 years old
  • Osteosarcoma that has relapsed, progressed or become refractory to conventional therapy
View Trial

PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors

Diseases Treated:

Recurrent, progressive, or refractory high-grade gliomas

Eligibility:

  • Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
  • Participant is 1 to 18 years of age
  • Participant has bi-measurable disease on MRI 
  • Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks

 

View Trial

SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

Diseases Treated:

Metastatic sarcomas

Eligibility:

  • Participant has histologically or cytologically confirmed diagnosis:
    • Nonrhabdomyosarcoma of soft tissue
    • Ewing sarcoma
    • Osteosarcoma at any site
  • Participant must be greater than 3 years of age and < 40 years of age.
  • Participant has not had any prior radiotherapy to the treatment site.
View Trial